Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 53.50% is 79% below its 5-year average of 258.49%, near the low end of its 5-year range (51.69%–580.87%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.35% below its 12-month average of 57.13%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 53.50%.
RETURN ON EQUITY (ROE)
53.50%
RETURN ON EQUITY (ROE) AVG TTM
57.13%
RETURN ON EQUITY (ROE) AVG 3Y
67.87%
RETURN ON EQUITY (ROE) AVG 5Y
258.49%
RETURN ON EQUITY (ROE) AVG 10Y
225.58%
RETURN ON EQUITY (ROE) AVG 15Y
71.63%
RETURN ON EQUITY (ROE) AVG 20Y
58.80%
CURRENT VS TTM AVG
-6.35%
CURRENT VS 3Y AVG
-21.17%
CURRENT VS 5Y AVG
-79.30%
CURRENT VS 10Y AVG
-76.28%
CURRENT VS 15Y AVG
-25.31%
CURRENT VS 20Y AVG
-9.01%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+311.24%
vs the sector median at left
Novo Nordisk A/S
Market Cap
$188.86B
Return on Equity (ROE)
53.50%
TTM Avg
57.13%
3Y Avg
67.87%
5Y Avg
258.49%
Market Cap
$181.64B
Return on Equity (ROE)
-27.39%
TTM Avg
19.98%
3Y Avg
21.60%
5Y Avg
19.44%
Market Cap
$176.59B
Return on Equity (ROE)
10.61%
TTM Avg
20.32%
3Y Avg
18.59%
5Y Avg
17.97%
Market Cap
$202.74B
Return on Equity (ROE)
74.80%
TTM Avg
79.33%
3Y Avg
111.35%
5Y Avg
101.76%
Market Cap
$157.02B
Return on Equity (ROE)
5.09%
TTM Avg
9.04%
3Y Avg
13.32%
5Y Avg
16.07%
Market Cap
$147.13B
Return on Equity (ROE)
7.61%
TTM Avg
7.38%
3Y Avg
9.51%
5Y Avg
10.24%
Market Cap
$238.35B
Return on Equity (ROE)
13.25%
TTM Avg
12.70%
3Y Avg
13.51%
5Y Avg
15.24%
Market Cap
$133.24B
Return on Equity (ROE)
17.28%
TTM Avg
15.07%
3Y Avg
13.91%
5Y Avg
13.46%
Market Cap
$130.62B
Return on Equity (ROE)
21.76%
TTM Avg
8.96%
3Y Avg
15.60%
5Y Avg
19.47%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $188.86B | 53.50% | 57.13% | 67.87% | 258.49% |
| Gilead Sciences, Inc. (GILD)vs › | $181.64B | -27.39% | 19.98% | 21.60% | 19.44% |
| Abbott Laboratories (ABT)vs › | $176.59B | 10.61% | 20.32% | 18.59% | 17.97% |
| Amgen Inc. (AMGN)vs › | $202.74B | 74.80% | 79.33% | 111.35% | 101.76% |
| Pfizer Inc. (PFE)vs › | $157.02B | 5.09% | 9.04% | 13.32% | 16.07% |
| Danaher Corporation (DHR)vs › | $147.13B | 7.61% | 7.38% | 9.51% | 10.24% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $238.35B | 13.25% | 12.70% | 13.51% | 15.24% |
| Intuitive Surgical, Inc. (ISRG)vs › | $133.24B | 17.28% | 15.07% | 13.91% | 13.46% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $130.62B | 21.76% | 8.96% | 15.60% | 19.47% |
| Bristol-Myers Squibb Company (BMY)vs › | $130.18B | 41.59% | -8.30% | 7.76% | 4.45% |
ROE
53.5%
ROA
19.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 53.50% |
| 2026-03-31 | 60.74% |
| 2025-12-31 | 51.69% |
| 2025-09-30 | 57.91% |
| 2025-06-30 | 61.81% |
| 2025-03-31 | 75.10% |
| 2024-12-31 | 73.19% |
| 2024-09-30 | 77.16% |
| 2024-06-30 | 557.56% |
| 2024-03-31 | 90.62% |
| 2023-12-31 | 77.00% |
| 2023-09-30 | 580.87% |
| 2023-06-30 | 493.54% |
| 2023-03-31 | 507.93% |
| 2022-12-31 | 65.34% |
| 2022-09-30 | 568.17% |
| 2022-06-30 | 512.52% |
| 2022-03-31 | 513.12% |
| 2021-12-31 | 69.13% |
| 2021-09-30 | 457.23% |
| 2021-06-30 | 424.14% |
| 2021-03-31 | 462.15% |
| 2020-12-31 | 381.32% |
| 2020-09-30 | 425.07% |
| 2020-06-30 | 451.65% |
| 2020-03-31 | 508.18% |
| 2019-12-31 | 448.79% |
| 2019-09-30 | 75.39% |
| 2019-06-30 | 71.05% |
| 2019-03-31 | 83.01% |
| 2018-12-31 | 76.54% |
| 2018-09-30 | 83.06% |
| 2018-06-30 | 81.64% |
| 2018-03-31 | 84.64% |
| 2017-12-31 | 72.99% |
| 2017-09-30 | 77.41% |
| 2017-06-30 | 76.55% |
| 2017-03-31 | 98.00% |
| 2016-12-31 | 88.05% |
| 2016-09-30 | 90.22% |
| 2016-06-30 | 84.75% |
| 2016-03-31 | 90.40% |
| 2015-12-31 | 74.95% |
| 2015-09-30 | 77.18% |
| 2015-06-30 | 82.64% |
| 2015-03-31 | 105.49% |
| 2014-12-31 | 70.90% |
| 2014-09-30 | 72.86% |
| 2014-06-30 | 70.55% |
| 2014-03-31 | 74.84% |
| 2013-12-31 | 57.02% |
| 2013-09-30 | 61.79% |
| 2013-06-30 | 68.08% |
| 2013-03-31 | 67.70% |
| 2012-12-31 | 52.08% |
| 2012-09-30 | 57.58% |
| 2012-06-30 | 62.21% |
| 2012-03-31 | 55.37% |
| 2011-12-31 | 48.24% |
| 2011-09-30 | 47.76% |
| 2011-06-30 | 40.94% |
| 2011-03-31 | 41.18% |
| 2010-12-31 | 38.43% |
| 2010-09-30 | 36.52% |
| 2010-06-30 | 39.39% |
| 2010-03-31 | 36.09% |
| 2009-12-31 | 29.55% |
| 2009-09-30 | 29.57% |
| 2009-06-30 | 30.98% |
| 2009-03-31 | 34.98% |
| 2008-12-31 | 31.13% |
| 2008-09-30 | 27.65% |
| 2008-06-30 | 22.84% |
| 2008-03-31 | 26.32% |
| 2007-12-31 | 25.12% |
| 2007-09-30 | 26.69% |
| 2007-06-30 | 25.89% |
| 2007-03-31 | 22.79% |
| 2006-12-31 | 20.68% |
| 2006-09-30 | 20.52% |
| 2006-06-30 | 19.53% |
| 2006-03-31 | 21.48% |
| 2005-12-31 | 21.87% |
| 2005-09-30 | 24.07% |
| 2005-06-30 | 22.99% |
| 2005-03-31 | 19.86% |
| 2004-12-31 | 17.56% |
| 2004-09-30 | 19.17% |
